$152 Million is the total value of Iguana Healthcare Management, LLC's 62 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MRK | MERCK & CO INC | $4,358,000 | -3.2% | 80,000 | 0.0% | 2.87% | -2.2% | |
| BMY | BRISTOL MYERS SQUIBB CO | $3,163,000 | +3.2% | 50,000 | 0.0% | 2.08% | +4.3% | |
| ADMA | ADMA BIOLOGICS INC | $2,760,000 | +43.3% | 600,000 | 0.0% | 1.82% | +44.8% | |
| CTLT | CATALENT INC | $1,232,000 | 0.0% | 30,000 | 0.0% | 0.81% | +1.0% | |
| ADVM | ADVERUM BIOTECHNOLOGIES INC | $1,160,000 | +65.7% | 200,000 | 0.0% | 0.76% | +67.3% | |
| DERM | DERMIRA INC | $799,000 | -71.3% | 100,000 | 0.0% | 0.53% | -71.0% | |
| OMED | ONCOMED PHARMACEUTICALS INC | $477,000 | -22.4% | 150,000 | 0.0% | 0.31% | -21.7% | |
| MRNS | MARINUS PHARMACEUTICALS INC | $382,000 | -53.2% | 100,000 | 0.0% | 0.25% | -52.7% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOGEN INC | 17 | Q1 2018 | 7.5% |
| ULTRAGENYX PHARMACEUTICAL IN | 17 | Q1 2018 | 6.7% |
| MERCK & CO INC NEW | 16 | Q1 2018 | 5.4% |
| CELGENE CORP | 15 | Q4 2017 | 7.9% |
| AERIE PHARMACEUTICALS INC | 15 | Q4 2017 | 3.3% |
| GILEAD SCIENCES INC | 14 | Q1 2017 | 6.7% |
| ESPERION THERAPEUTICS INC NE | 14 | Q1 2018 | 7.8% |
| SUPERNUS PHARMACEUTICALS INC | 14 | Q4 2017 | 2.8% |
| DERMIRA INC | 14 | Q1 2018 | 2.7% |
| AMGEN INC | 13 | Q1 2017 | 6.5% |
View Iguana Healthcare Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2018-05-15 |
| 13F-HR | 2018-02-14 |
| 13F-HR/A | 2017-11-16 |
| 13F-HR | 2017-11-14 |
| 13F-HR | 2017-08-14 |
| 13F-HR | 2017-05-15 |
| 13F-HR | 2017-02-14 |
| 13F-HR/A | 2016-11-17 |
| 13F-HR | 2016-11-14 |
| 13F-HR/A | 2016-11-04 |
View Iguana Healthcare Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.